- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.10. | Ipsen buys ImCheck, adding mid-stage leukaemia drug | ||
| 22.10. | Takeda builds in cancer with monster $11.4bn Innovent deal | ||
| 22.10. | UK start-up Procyon has pancreatic cancer test in its sights | ||
| 21.10. | Galapagos abandons cell therapy, putting 365 jobs at risk | ||
| 21.10. | Novo Nordisk's chairman quits amid Foundation row | ||
| 21.10. | GSK will file oral carbapenem for complicated UTIs this year | ||
| 20.10. | Joy as retinal implant restores sight in geographic atrophy | ||
| 20.10. | ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer | ||
| 20.10. | ESMO: Datroway, Trodelvy lay claim to frontline TNBC therapy | ||
| 20.10. | ESMO: Clear air emerges between Roche SERD and its rivals | ||
| 20.10. | CHMP backs first drug for lung disease bronchiectasis | ||
| 20.10. | Amgen, AZ's Tezspire challenges Dupixent in nasal polyps | ||
| 17.10. | ESMO: Lilly reveals scale of survival win with Verzenio | ||
| 17.10. | Could endometriosis be diagnosed with a simple test? | ||
| 17.10. | ViiV's bimonthly HIV PrEP jab cleared for use by NHS | ||
| 17.10. | Lila Sciences' swollen first round, and other biofinancings | ||
| 17.10. | Merck KGaA joins the Trump MFN gang with IVF deal | ||
| 17.10. | FDA hands out first national priority vouchers to nine firms | ||
| 16.10. | UK starts 'largest-ever' trial of possible Parkinson's drugs | ||
| 16.10. | Merck KGaA looking to rare disease deals to build health momentum | ||
| 16.10. | J&J faces fresh litigation in UK over talc cancer risks | ||
| 16.10. | Bavarian Nordic urges investors to accept takeover offer | ||
| 15.10. | Novo builds pipeline again with $2.1bn Omeros deal | ||
| 15.10. | UK's VR-powered medicine maker scheme delivers first results | ||
| 15.10. | Lilly says oral GLP-1 could be 'foundational' diabetes drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .